

**"People without regular incomes or any financial cushion deserve social policies that ensure dignity and enable them to comply with #COVID19 public health measures advised by national health authorities and WHO. - WHO DG, Dr. Tedros Adhanom Ghebreyesus**

## Highlight

- A total of 57,296 (3,279 today) confirmed cases from 21 countries in the East Mediterranean Region and total deaths are at 3,253 (140 today).
- Lebanon is still in level 3 of COVID 19 transmission scenarios "Lebanon is experiencing cases clusters in time, geographic location and/or common exposure (Clusters of cases)".
- As mentioned by the Director-General in his regular media briefing yesterday, ensuring free movement of essential health products is vital for saving lives and curbing the social and economic impacts of the pandemic. WHO is working intensively with partners to increase access to life-saving products, including diagnostics, PPE, medical oxygen, ventilators and more.
- Starting Thursday 2 April 2020 at noon the current call center number will be replaced with **01-594459**.

## Global update

as per WHO dashboard 01 April 2020 at 9pm

<b>Globally cases</b>	<b>823,626</b> (68,678 new)
<b>Countries, areas or territories with cases</b>	<b>205 countries</b> (3 new)
<b>Total deaths</b>	<b>40,598</b> (4,027new) (CFR: 3.4%)
<b>Confirmed cases in China</b>	<b>82,631</b> (86 new)
<b>Confirmed cases in USA</b>	<b>163,199</b> ( 22,559)
<b>Confirmed cases in Italy</b>	<b>105,792</b> (4,053)
<b>Confirmed cases in Spain</b>	<b>94,417</b> (9,222)

**WHO RISK ASSESSMENT**  
**Global Level - Very High**




Figure 1. Countries, territories or areas with reported confirmed cases of COVID-19, 31 March 2020

# Distribution of COVID-19 cases as reported by the Epidemiological Surveillance Unit at the MOPH dashboard at 4pm

## COVID-19 Surveillance in Lebanon

01 APRIL 2020 UPDATE

Figure 1: Cases by age group




Figure 2: Cases by source of exposure




Figure 3: Cases by clinical presentation





Figure 4: Cases by date of confirmation



**479<sup>¥</sup> Cumulative cases of COVID-19**

- 16 new cases
- 38 healthcare workers
- 12 associated deaths

**Call center:**

- 3742 Cumulative calls received
- 293 referred to RHUH

Table 1: Distribution of fatalities by age group


Age (years)	Deaths (n)	CFR
<10y	0	0.0%
10-19y	0	0.0%
20-29y	0	0.0%
30-39y	0	0.0%
40-49y	1	1.3%
50-59y	3	3.8%
60-69y	1	2.2%
70-79y	5	13.5%
80+y	2	10.0%
<b>Total</b>	<b>12</b>	<b>2.5%</b>

\* Cases under investigation have not yet been classified by exposure

\*\* Addition of new reporting laboratories






¥ 78.28% recovered or mild cases at home, 19.22% hospitalized (17.12% admitted to regular ward, 2.10% ICU), case fatality of 2.5%

Map 1 : Cases by district of residence  
Date: 01-Apr-20





## Several early investigation master protocols for COVID-19 summarized below:

	Which early investigations?	For whom?	Why?
	The First Few COVID-19 X cases and contacts transmission investigation protocol (FFX)	Cases and close contacts in the general population or can be restricted to close settings (like households, health care settings, schools).	Community transmission mainly (or closed settings)
	Household transmission of COVID-19 investigation protocol (HH)	Cases and close contacts in household setting	Households transmission
	Assessment of COVID-19 risk factors among Health workers (HW) protocol	For health workers in a healthcare setting in which a confirmed case has received care	Health facilities transmission
	Population-based age-stratified seroepidemiological investigation protocol for COVID-19	Virus infection in the general population	Community infection
	Surface sampling of COVID-19 virus: A practical "how to" protocol for health care and public health professionals	For environmental surfaces	Surface contamination and transmission





## WHO launched the international Solidarity Clinical Trial for COVID-19 cases

In early 2020 there were no approved anti-viral treatments for COVID, and WHO expert groups advised that four repurposed drugs, Remdesivir, Lopinavir (given with Ritonavir, to slow hepatic degradation), Interferon ( $\beta$ 1a), and chloroquine or hydroxychloroquine should be evaluated in an international randomised trial. WHO has provided guidelines that local physicians may consider when COVID-19 is suspected on [clinical management of severe acute respiratory infection](#). The hospital willing to adhere to this international trial should obtain the institution's ethical approval (IRB) and the patient's consent

Adults (age  $\geq 18$  years) recently hospitalised, or already in hospital, with confirmed COVID infection and, based on the responsible doctor assessment, have no contra-indication to any of the study drugs will be randomly allocated between

- Local standard of care alone,  
OR local standard of care plus one of
- Remdesivir (daily infusion for 10 days)
- Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)
- Lopinavir with Ritonavir (orally twice daily for 14 days)
- Lopinavir with Ritonavir (ditto) plus Interferon (daily injection for 6 days).

All information is entered electronically and managed at WHO headquarters

The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation. The major secondary outcomes are duration of hospital stay and time to first receiving ventilation (or intensive care) A global Data and Safety Monitoring Committee will keep the accumulating drug safety results and major outcome results under regular review.

## Case Management of COVID-19 suspected patients

- Anyone who came in close contact with a COVID-19 patient should self-isolate at home. If within 14 days symptoms develop (cough, sore throat, fever, shortness of breath then call MOPH Call Center 01-594459.
  - Self-isolation at home where there are other family members should be in a well-ventilated room. No contact should be made with the household members. Food or other items should be put outside the door. Bathroom should not be shared with others except if there is only one bathroom in the house. In this case bathroom/toilet should be thoroughly cleaned (disinfected) after each use by the isolated person.
- Suspected cases who develop symptom cough, fever and sore throat should call MOPH Call Center 01-594459. Medical team who handle Call Center are professionals and well-placed to give proper instructions on what to do. Instructions should be obeyed thoroughly to stay safe and to protect people around you.
  - If a person is asked to take the COVID-19 test then its best to visit the closest hospital near you. Team on the phone will advise.
- When a person tests positive in laboratory-confirmed cases, the person will either be advised to self-isolation (mild symptoms) or be admitted to a medical facility.



## WHO guide

- [Operational considerations for case management of COVID-19 in health facility and community](#) – A guide for the care of COVID-19 patients as the response capacity of health systems is challenged; to ensure that COVID-19 patients can access life-saving treatment, without compromising public health objectives and safety of health workers.

Useful Links	Important numbers	
<ul style="list-style-type: none"><li>➤ WHO real time <a href="#">dashboard</a></li><li>➤ WHO <a href="#">COVID-19 page</a></li><li>➤ Protect yourself (<a href="#">English</a>/<a href="#">Arabic</a>)</li><li>➤ Q&amp;A (<a href="#">English</a>/<a href="#">Arabic</a>)</li><li>➤ WHO Lebanon <a href="#">website</a></li><li>➤ WHO Lebanon <a href="#">Facebook</a> <a href="#">Twitter</a> <a href="#">Instagram</a></li></ul>	<ul style="list-style-type: none"><li>➤ MOPH Hotline 1214</li><li>➤ Airport quarantine section 01-629352</li><li>➤ Preventive medicine center 01-843769   01830300</li><li>➤ Call Centre 76-592699</li></ul>	<ul style="list-style-type: none"><li>➤ Preventive medicine center 01-843769   01-830300</li><li>➤ Call Centre 76-592699</li><li>➤ Epidemiological Surveillance Unit 01-614194   01-614196</li></ul>
For more information Hala Habib   Communication Consultant   +961 3 870459		